Kazia Therapeutics Book Value Per Share Growth & History (KZIA)
Kazia Therapeutics's book value per share was -A$0.01 for fiscal 2025.
View full Kazia Therapeutics company overviewKazia Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | -A$0.01 | A$0.02 | — |
| 2024 | 2024-06-30 | -A$0.03 | -A$0.08 | — |
| 2023 | 2023-06-30 | A$0.05 | -A$0.08 | −59.88% |
| 2022 | 2022-06-30 | A$0.13 | -A$0.16 | −54.06% |
| 2021 | 2021-06-30 | A$0.29 | A$0.14 | +92.03% |
| 2020 | 2020-06-30 | A$0.15 | -A$0.08 | −34.61% |
| 2019 | 2019-06-30 | A$0.23 | -A$0.17 | −42.55% |
| 2018 | 2018-06-30 | A$0.40 | A$0.34 | +633.90% |
| 2017 | 2017-06-30 | A$0.05 | -A$0.03 | −31.77% |
| 2016 | 2016-06-30 | A$0.08 | — | — |
Kazia Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2025-12-31 | A$0.01 | A$0.02 | — |
| Q4 2025 | 2025-06-30 | -A$0.01 | A$0.02 | — |
| Q2 2025 | 2024-12-31 | -A$0.01 | — | — |
| Q4 2024 | 2024-06-30 | -A$0.03 | -A$0.08 | — |
| Q4 2023 | 2023-06-30 | A$0.05 | -A$0.08 | −59.88% |
| Q4 2022 | 2022-06-30 | A$0.13 | -A$0.16 | −54.06% |
| Q4 2021 | 2021-06-30 | A$0.29 | A$0.14 | +92.03% |
| Q4 2020 | 2020-06-30 | A$0.15 | -A$0.08 | −34.61% |
| Q4 2019 | 2019-06-30 | A$0.23 | -A$0.17 | −42.55% |
| Q4 2018 | 2018-06-30 | A$0.40 | -A$0.13 | −24.06% |
| Q4 2017 | 2017-06-30 | A$0.52 | — | — |
Kazia Therapeutics book value per share trends
Over the last five fiscal years, Kazia Therapeutics's book value per share decreased from A$0.15 to -A$0.01, a change of -A$0.16. The latest reported quarter, Q2 2026, shows A$0.01.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kazia Therapeutics source filings ↗